An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK).
An adoptive immunotherapy of 6 patients with medulloblastoma by lymphokine-activated killer (LAK) cells is described. They were from 2 to 9 years in age and had cerebrospinal fluid (CSF) dissemination of the tumours. All patients underwent the whole-neuraxis irradiation and chemotherapy. After the usual treatments, they were submitted to an adoptive transfer of one-haplotype identical LAK cells. The LAK cells were induced from peripheral blood lymphocytes (PBL) of their relatives with human recombinant interleukin-2 (rIL-2). 3 - 15 x 10(9) LAK cells were transferred intrathecally in 2-3 months. In 3 of 6 patients, neurological signs were improved and malignant cells had never been detected on CSF cytology after the adoptive immunotherapy. One among these 3 patients showed complete response in 20 months. Thus, this is an attractive approach for the treatment of medulloblastoma with CSF dissemination of the tumour which current therapeutic intervention can not cure.
Okamoto
Y
Y
Department of Neurosurgery, Osaka University Medical School, Japan.
Shimizu
K
K
Tamura
K
K
Miyao
Y
Y
Yamada
M
M
Matsui
Y
Y
Tsuda
N
N
Takimoto
H
H
Hayakawa
T
T
Mogami
H
H
D002528:Cerebellar Neoplasms / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007167:Immunotherapy; D007694:Killer Cells, Natural / Q000637:transplantation*; D008222:Lymphokines / Q000494:pharmacology*; D008297:Male; D008527:Medulloblastoma / Q000628:therapy*; D011994:Recombinant Proteins / Q000494:pharmacology
D008222:Lymphokines; D011994:Recombinant Proteins